EpiBiologics, a biotechnology company focused on novel therapeutic approaches, has secured $107.0 million in new investment capital. The company is advancing bispecific antibodies designed to selectively degrade membrane and soluble proteins, including GPCRs. Its proprietary EpiTAC platform leverages a novel atlas of tissue-selective degrader receptors to drive deep and durable efficacy, aiming to develop treatments for various diseases by precisely targeting disease-causing proteins.
Founded in 2022, EpiBiologics emerged from pioneering work conducted by Dr. Jim Wells at the University of California, San Francisco (UCSF). This substantial capital infusion underscores investor confidence in the company's innovative platform and its potential to address significant unmet medical needs. Headquartered in the SF Bay Area, EpiBiologics is actively building a clinical stage pipeline with a focus on oncology and immunology, areas where targeted protein degradation could offer new therapeutic avenues.
The newly raised funds are intended to accelerate the development of EpiBiologics' pipeline of bispecific antibodies and to further expand the capabilities of its EpiTAC platform. This investment will support the company's ongoing research and development efforts, enabling the progression of its therapeutic candidates towards clinical trials. EpiBiologics plans to leverage this capital to advance its innovative programs, strengthen its scientific team, and solidify its position in the targeted protein degradation space, driving its growth initiatives and ultimately bringing new therapies to patients.
